BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 37065576)

  • 1. Construction and validation of a tumor mutational burden and immune-related prognostic model for predicting the prognosis of patients with lung squamous cell carcinoma.
    Zhou Y; Xu M; Zhao K; Liu B
    J Thorac Dis; 2023 Mar; 15(3):1319-1334. PubMed ID: 37065576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients.
    Yan D; Chen Y
    Sci Rep; 2021 Apr; 11(1):9020. PubMed ID: 33907270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
    Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
    Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of
    Lin H; Wang J; Shi Q; Wu M
    PeerJ; 2024; 12():e17338. PubMed ID: 38708353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
    Pan J; Huang Z; Lin H; Cheng W; Lai J; Li J
    BMC Cancer; 2022 Nov; 22(1):1132. PubMed ID: 36333719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.
    Huang H; Wu W; Lu Y; Pan X
    J Thorac Dis; 2022 Oct; 14(10):4055-4072. PubMed ID: 36389308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a prognostic model for lung squamous cell carcinoma based on immune-related genes.
    Pu J; Teng Z; Yang W; Zhu P; Zhang T; Zhang D; Wang B; Hu Z; Song Q
    Carcinogenesis; 2023 May; 44(2):143-152. PubMed ID: 36455238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
    Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
    J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
    Zhang Y; Zhou J; Li H; Liu Y; Li J
    BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.
    Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y
    Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791
    [No Abstract]   [Full Text] [Related]  

  • 14. A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma.
    Wang X; Meng Y; Liu C; Yang H; Zhou S
    J Oncol; 2022; 2022():9103259. PubMed ID: 36131791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas.
    Liu Y; Xiang J; Peng G; Shen C
    Front Oncol; 2022; 12():620190. PubMed ID: 35800054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Model for Lower-Grade Glioma.
    Yin W; Jiang X; Tan J; Xin Z; Zhou Q; Zhan C; Fu X; Wu Z; Guo Y; Jiang Z; Ren C; Tang G
    Front Oncol; 2020; 10():1409. PubMed ID: 32974146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.
    Ti W; Wei T; Wang J; Cheng Y
    Front Immunol; 2022; 13():947712. PubMed ID: 35935970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
    Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
    DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Pyroptosis-Related Gene Signature for Early-Stage Lung Squamous Cell Carcinoma.
    Li X; He J
    Int J Gen Med; 2021; 14():6439-6453. PubMed ID: 34675612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.